v3.25.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 5,742 $ 25,030
Short-term investments 7,970 17,466
Restricted cash 0 146
Accounts receivable 1,913 1,482
Inventories 0 10,655
Other current assets 2,807 10,115
Total current assets 18,432 64,894
Property and equipment, net 147 1,294
Operating lease assets 10,707 39,807
Other assets 881 3,103
Total assets 30,167 109,098
Current liabilities:    
Accounts payable 318 4,367
Accrued compensation 2,067 6,589
Accrued research and development expenses 342 7,984
Deferred revenue 1,011 95,092
Liability related to the sale of future revenues - current portion 9,670 382
Other current liabilities 4,649 20,160
Total current liabilities 18,057 134,574
Operating lease liabilities - long-term 15,005 29,914
Liability related to the sale of future revenues - long-term 31,976 38,624
Other long-term liabilities 1,763 3,269
Total liabilities 66,801 206,381
Commitments and contingencies (Note 9)
Stockholders' equity (deficit):    
Common stock - $0.0001 par value, 500,000 shares authorized as of September 30, 2025 and December 31, 2024; 7,210 and 5,859 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 1 1
Additional paid-in capital 1,981,822 1,957,261
Accumulated other comprehensive income (loss) 2 8
Accumulated deficit (2,018,459) (2,054,553)
Total stockholders' equity (deficit) (36,634) (97,283)
Total liabilities and stockholders' equity (deficit) $ 30,167 $ 109,098

Source

10-Q
HTML PDF
XBRL
ZIP